SLU-PP-332

SLU-PP-332 from Super Human Peptides UK is a highly advanced synthetic small molecule. In laboratory research, it is classified as a potent, non-selective pan-estrogen-related receptor (ERR) agonist, exhibiting its highest binding affinity for the ERRα isoform. Researchers heavily utilize SLU-PP-332 as a groundbreaking "exercise mimetic."

Under normal physiological conditions, physical endurance exercise activates ERR receptors to trigger metabolic adaptations in skeletal muscle. SLU-PP-332 allows researchers to pharmacologically induce these exact adaptations without physical exertion. By activating the ERR pathways, the compound upregulates genes responsible for mitochondrial biogenesis, forces the body into elevated fatty acid oxidation, and drastically enhances cellular respiration.

Produced under GMP-compliant conditions and verified for 99% purity or higher, SLU-PP-332 is a premier model for investigating treatments for metabolic syndrome, obesity, age-related muscle dysfunction, and extreme endurance enhancement.

• —Pan-ERR Agonist: Binds to ERRα, ERRβ, and ERRγ receptors to trigger massive metabolic shifts.
• —Exercise Mimetic: Pharmacologically induces the physiological adaptations normally only achieved through aerobic exercise.
• —Mitochondrial Biogenesis: Promotes the creation of new mitochondria within skeletal muscle cells, improving overall cellular energy output.
• —Fat Oxidation Shift: Forces the metabolism to prioritize the burning of fatty acids over carbohydrates.
• —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
• —Quality Standard: GMP / ISO certified manufacturing.

• —Receptor Affinity: Studying the dose-dependent activation of ERRα, ERRβ, and ERRγ receptors and the downstream transcription of target genes (such as PGC-1α).
• —Endurance and Stamina: Measuring the pharmacological enhancement of physical running capacity and fatigue resistance in animal models.
• —Metabolic Syndrome and Obesity: Investigating the rapid reduction of fat mass, improvement of insulin sensitivity, and reversal of diet-induced obesity without caloric restriction.
• —Muscle Fiber Type Shifting: Researching the conversion of skeletal muscle fibers into highly oxidative, fatigue-resistant Type IIa fibers.
• —Hepatic and Renal Function: Preclinical models exploring the reduction of hepatic triglycerides and restoration of organ mitochondrial respiration in aged subjects.

SLU-PP-332 has recently captured massive attention in the fields of metabolic and gerontological research. Groundbreaking laboratory studies led by researchers at the University of Florida and Washington University demonstrated that ERR activation is the primary molecular trigger for the benefits of exercise. In landmark animal studies, mice administered SLU-PP-332 exhibited a staggering 70% increase in their running endurance compared to control groups.

Furthermore, in models of diet-induced obesity, subjects treated with the compound gained significantly less fat and maintained vastly superior metabolic profiles despite consuming high-fat diets, effectively mimicking the caloric burn and lipid oxidation of intense daily cardio. Because it acts directly on the nuclear receptors responsible for cellular energy, it is considered one of the most promising novel pathways for combatting age-related metabolic decline and severe obesity.